The goal of this clinical trial is to compare two treatments for regulating blood flow in small liver grafts during living donor liver transplantation (LDLT). The main questions it aims to answer are:
* Is octreotide (a medication) as effective or better than splenic artery ligation (surgery) in reducing complications after transplantation? * Which treatment better controls blood flow while causing fewer side effects?
Researchers will compare octreotide (given through an IV) to splenic artery ligation (performed during surgery) to see which approach works best for patients receiving small liver grafts.
Participants will:
* Be randomly assigned to receive either octreotide or splenic artery ligation during their transplant surgery * Have their liver blood flow monitored closely during and after surgery
Be followed for 90 days and 1 year to track complications, hospital stay, recovery, and survival.
This study may help doctors choose safer, more effective treatments for patients needing small liver grafts.
Age ≥ 18 and <70 years
Male and female genders
Undergoing Living Donor Liver Transplant (LDLT)
All indications
Deceased Donor Liver Transplantation (DDLT)
Dual LDLT or dual LDLT/DDLT
Pregnancy
Known allergy to Octreotide / Somatostatin analogue